Malaria Treatment & Artemisinin-Based Combination Therapies

Artemisinin-based combination therapy is the WHO-recommended backbone of falciparum malaria treatment. We supply the full EML-listed ACT range plus the parenteral and rectal artemisinins used in severe malaria and pre-referral care.

15 products ACT tablets & dispersibles · parenteral artesunate & artemether · rectal artesunate · quinine
5 sourced statements Reference: WHO Model List of Essential Medicines, 24th List (September 2025) Reviewed 2026-10-05

An artemisinin-based combination therapy (ACT) pairs a fast-acting artemisinin derivative with a longer-acting partner drug so that each protects the other against resistance. WHO recommends a three-day ACT course as the treatment of choice for uncomplicated P. falciparum malaria in all trimesters, and parenteral artesunate for severe malaria.

At a glance

  • WHO recommends a three-day ACT course for uncomplicated falciparum malaria in all trimesters.
  • The WHO Model List specifies six ACT combinations and their exact strengths.
  • Parenteral artesunate at 2.4 mg/kg is the drug of choice for severe malaria; artemether is the intramuscular alternative.
  • Rectal artesunate is for pre-referral use only — a single 10 mg/kg dose.
  • We supply 15 antimalarial products across tablet, suspension, injection, suppository and granule forms.

01What the published guidance says

Every statement below is drawn from WHO or MSF published material and linked to its source. We summarise; we do not reproduce. Statements marked as our own are commercial positions, not clinical guidance.

ACT is the treatment of choice in all trimesters

For uncomplicated P. falciparum malaria, MSF medical guidelines state the treatment of choice in all trimesters is an artemisinin-based combination therapy taken for three days. Co-formulated and co-blistered regimens are both described, including artemether/lumefantrine 20/120 mg and 80/480 mg, artesunate/amodiaquine, artesunate/mefloquine and dihydroartemisinin/piperaquine.

The ACT combinations and their strengths are specified on the WHO Model List

Section 6.5.3.1 of the 24th WHO Model List (2025) specifies the curative antimalarials, including artemether + lumefantrine tablet 20 mg + 120 mg and a dispersible tablet, artesunate + amodiaquine, artesunate + mefloquine, artesunate + pyronaridine as granules and tablets, dihydroartemisinin + piperaquine across four tablet strengths, and artesunate co-packaged with sulfadoxine + pyrimethamine.

For severe malaria, parenteral artesunate is the drug of choice

WHO guidance is artesunate 2.4 mg/kg by intravenous or intramuscular injection on admission, again at 12 and 24 hours, then once daily. Where artesunate is unavailable, intramuscular artemether 3.2 mg/kg on admission followed by 1.6 mg/kg daily is the alternative — artemether must never be given by the intravenous route. Parenteral treatment continues for at least 24 hours before switching to a full three-day oral ACT course.

Pre-referral rectal artesunate buys time in the first 24 hours

Because the risk of death from severe malaria is greatest during the first day, WHO recommends a single pre-referral dose by the parenteral or intrarectal route. Artesunate suppositories are given at 10 mg/kg as a single dose, in 50 mg or 200 mg formulations. The Model List carries a 100 mg rectal dosage form, restricted to pre-referral treatment of severe malaria only.

One combination to handle with care

MSF notes that the artesunate + sulfadoxine/pyrimethamine combination is contraindicated in HIV-infected women taking co-trimoxazole preventive therapy, and that artesunate/mefloquine should not be used where neurological signs developed during the acute phase.

02Products in this therapeutic group

Each entry links to its full specification page.

Products supplied by Sinophare Bio-technology Co., Ltd. in the Malaria & ACTs therapeutic area
Product Dosage form Presentation notes Detail
Artemether-Lumefantrine Suspension 180/1080mg Suspension   View Artemether-Lumefantrine Suspension 180/1080mg →
Artesunate Suspension 10mg/5mL 80mL Suspension Antimalarial View Artesunate Suspension 10mg/5mL 80mL →
Artemether Suspension 15mg/5mL 60mL Suspension Antimalarial View Artemether Suspension 15mg/5mL 60mL →
Artesunate 80mg Powder for Injection Injection Severe Malaria View Artesunate 80mg Powder for Injection →
Quinine Dihydrochloride Injection Injection   View Quinine Dihydrochloride Injection →
Artemether/Lumefantrine 80/480mg Tablet   View Artemether/Lumefantrine 80/480mg →
Artesunate /Mefloquine 400mg/500mg Tablet   View Artesunate /Mefloquine 400mg/500mg →
Artesunate 200mg + Amodiaquine 600mg Tablets Tablet   View Artesunate 200mg + Amodiaquine 600mg Tablets →
Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg Tablet   View Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg →
Sulfadoxine/Pyrimethamine combined with Amodiaquine Tablet   View Sulfadoxine/Pyrimethamine combined with Amodiaquine →
Dihydroartemisinin 40mg and Piperaquine 320m Tablet   View Dihydroartemisinin 40mg and Piperaquine 320m →
Chloroquine Phosphate 500mg Tablets Tablet   View Chloroquine Phosphate 500mg Tablets →
Artesunate 20mg + Pyonaridine 60mg Granules Granules   View Artesunate 20mg + Pyonaridine 60mg Granules →
Artemether 80mg Injection Injection   View Artemether 80mg Injection →
Artesunate Suppositories 100mg Suppository Artemisinin Antimalarial Rectal Medication View Artesunate Suppositories 100mg →

15 products in this group · part of 186 finished dosage forms across 14 therapeutic areas.

03Specifying your order

The five things worth stating on a purchase order for this group, so the quotation comes back right first time.

Fixed-dose ratio

State the INN pair and ratio, e.g. artemether/lumefantrine 20/120 mg or 80/480 mg. Combination ratios are not interchangeable.

Blister configuration

ACTs are dispensed by weight band. Confirm the tablet count per blister and the pack that matches your national treatment guideline.

Dispersible or standard

Specify whether the paediatric presentation must be dispersible, and confirm the age or weight range it will be used for.

Injection reconstitution

For artesunate powder for injection, state the reconstitution volume expected, since dilution differs between the IV and IM routes.

Leaflet language

Patient information and prescribing leaflets must match the language your regulator requires for the destination market.

04How we supply it

Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.

Co-formulated and co-packaged

Fixed-dose combination tablets, dispersible paediatric tablets, dry suspensions and granules, plus the co-packaged artesunate – sulfadoxine/pyrimethamine presentation.

Parenteral and rectal

Artesunate powder for injection, artemether oily injection and artesunate suppositories for pre-referral use.

Paediatric-first

Weight-band dosing presentations suitable for national paediatric formularies, with dispersible options where the Model List specifies them.

Dossier-ready

COA, HPLC/GC data, stability packages, DMF and registration support for national antimalarial marketing-authorisation filings.

05Safety, labelling & regulatory notes

Points worth carrying into your tender, label review or clinical briefing.

  • Artesunate for injection is a powder for reconstitution — confirm reconstitution volume, because the dilution differs between the intravenous (10 mg/mL) and intramuscular (20 mg/mL) routes.
  • Artesunate suppositories are indicated only as a single pre-referral dose, never as definitive treatment. Referral must follow as soon as possible.
  • Do not use AS/MQ where neurological signs appeared during the acute phase; do not use AS/SP in HIV-infected women on co-trimoxazole preventive therapy.
  • Artesunate is a WHO-listed medicine with documented falsified circulation in some supply chains — verify batch documentation and the manufacturer's authorisation for your market.

06Questions buyers ask

6 answers covering specification, documentation and regulatory questions for this group.

What is the difference between artesunate and artemether for injection?
Artesunate is the WHO drug of choice for severe malaria and may be given intravenously or intramuscularly at 2.4 mg/kg. Artemether is an alternative given intramuscularly at 3.2 mg/kg on admission then 1.6 mg/kg daily, and must never be given intravenously.
Which ACT combinations appear on the WHO Model List?
The 24th List (2025) specifies artemether + lumefantrine, artesunate + amodiaquine, artesunate + mefloquine, artesunate + pyronaridine, dihydroartemisinin + piperaquine, artesunate co-packaged with sulfadoxine + pyrimethamine, and chloroquine restricted to P. vivax.
Do you supply dispersible paediatric ACTs?
Yes. We supply dispersible and dry-suspension presentations aligned to the strengths in the Model List, including artemether + lumefantrine 20/120 mg dispersible tablets and paediatric suspensions.
Can you support registration in my market?
We provide COA, HPLC and GC analytical data, stability data, DMF and dossier packages together with registration support documents. DML Number Jin20160068 covers our medicines production.
What strengths of artemether/lumefantrine do you supply?
Suspension 180/1080 mg, tablets 80/480 mg, and dispersible paediatric presentations aligned to the Model List specification of 20 mg artemether + 120 mg lumefantrine. Confirm the weight-band pack your national guideline uses.
Why can artemether not be given intravenously?
Artemether is an oily intramuscular injection. WHO guidance specifies the intramuscular route only, into the anterior thigh. For intravenous administration, artesunate is the medicine to use.

07Related therapeutic areas

Adjacent groups you may want to combine on one purchase order.

Request a quotation for Malaria & ACTs

Send us the products, strengths and pack sizes you need, together with the destination country, and we will return a quotation with the documentation package and lead time. Registration support documents are provided with every order.

Request a quotation →
Or write to info@sinophare.com